Annexin A1 pathways triggered in the inflammatory bowel disease treated with infliximab

• Grant number: 16/19682-2
• Support Opportunities: Scholarships in Brazil - Doctorate
• Effective date (Start): December 01, 2016
• Effective date (End): December 02, 2020
• Field of knowledge: Biological Sciences - Pharmacology - General Pharmacology
• Principal Investigator: Sandra Helena Poliselli Farsky
• Grantee: Marina de Paula Silva
• Host Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated research grant: 14/07328-4 - Identification of endogenous pathways for the control of inflammation, AP.TEM
• Associated scholarship(s): 19/02806-9 - Involvement of formyl-peptide receptor pathways and ligands in the efficacy of infliximab therapy, BE.EP.DR

Abstract

Inflammatory bowel diseases (IBDs) are characterized by severe inflammation in the gastrointestinal tract. The TNF-alpha exerts a benefitial role against infections during IBDs, but the dysregulation of this cytokine constitutes a key factor to the triggering and maintenance of intestinal inflammation. Therefore, TNF-alpha neutralizing tools, such as the anti-TNF-alpha antibody Infliximab (IFX) have been applied to induce remission of IBDs in conventional therapies refractory patients. Studies have shown that IFX regulates the endogenous expression of the anti-inflammatory protein annexin A1 (AnxA1). Besides, our research group recently demonstrated that AnxA1 participates of the IFX treatment efficacy. However, the mechanisms involved in the endogenous AnxA1 modulation and remission of IBDs after IFX remain unclear. Adverse events non-responsiveness after IFX are still reported, bringing the need to investigate the pathways through TNF-a, AnxA1 and IFX interact. Thus, our aim is assess the mechanisms of endogenous AnxA1 in the pathogenesis of IBDs and in IFX therapy efficacy, focused in the cells involved in these processes. First, we are going to investigate whether the AnxA1 acts via FPR and, still, the therapeutic effect of an AnxA1 mimetic peptide. DSS colitis model will be induced in WT and AnxA1-/- mice, which will be treated with either the pan FPR receptor antagonist, Boc-2, or the AnxA1 N-terminal peptide, Ac2-26, respectively. Both Boc-2 and Ac2-26 will be administered simultaneously with IFX to evaluate the relationship of the AnxA1 with this therapy. To highlight the pathways through AnxA1 is related to IBDs pathogenesis and IFX treatment, we will perform in vitro assays with epithelial cells (Caco-2), macrophages and dendritic cells derivated from human monocytes (U937), manipulated or not to the silencing of endogenous AnxA1. Finally, tridimensional culture with the same cell types above, positive or negative to AnxA1, will mimic the relationship between the main cells involved in the IBDs. We believe that the results obtained from the proposed experiments will contribute to the better understanding of the IBDs pathogenesis and the mechanisms involved in the efficacy of the anti-TNF-alpha treatment, providing important subsides to improve the existent therapies and, consequently, the life quality of the patients.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DA ROCHA, GUSTAVO HENRIQUE OLIVEIRA; DE PAULA-SILVA, MARINA; BROERING, MILENA FRONZA; SCHARF, PABLO RHASAN DOS SANTOS; MATSUYAMA, LARISSA SATIKO ALCANTARA SEKIMOTO; MARIA-ENGLER, SILVYA STUCHI; FARSKY, SANDRA HELENA POLISELLI. Pioglitazone-Mediated Attenuation of Experimental Colitis Relies on Cleaving of Annexin A1 Released by Macrophages. FRONTIERS IN PHARMACOLOGY, v. 11, DEC 21 2020. (16/19682-2, 17/05430-4, 14/07328-4)

DE PAULA-SILVA, MARINA; OLIVEIRA DA ROCHA, GUSTAVO HENRIQUE; BROERING, MILENA FRONZA; QUEIROZ, MARIA LUIZA; SANDRI, SILVANA; LOIOLA, RODRIGO AZEVEDO; OLIANI, SONIA MARIA; VIEIRA, ANDREA; PERRETTI, MAURO; POLISELLI FARSKY, SANDRA HELENA. Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn's Disease. FRONTIERS IN IMMUNOLOGY, v. 12, SEP 17 2021. (14/07328-4, 19/02806-9, 16/19682-2)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

SILVA, Marina de Paula. Annexin A1 pathways triggered in the inflammatory bowel disease treated with infliximab. 2020. Doctoral Thesis - Universidade de São Paulo (USP). Conjunto das Químicas (IQ e FCF) (CQ/DBDCQ) São Paulo.